These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 14575013)

  • 61. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
    Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of an ongoing educational program on the use of antiplatelet drugs, beta-blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs in patients with coronary artery disease seen in an academic cardiology clinic.
    Nayak D; Aronow WS
    Cardiol Rev; 2005; 13(2):95-7. PubMed ID: 15705260
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of Chinese guidelines for management of patients with acute myocardial infarction on outcomes of hospitalized patients.
    Jiang SL; Ji XP; Zhang C; Wang XR; Zhang M; Zhang Y
    Chin Med J (Engl); 2006 Jan; 119(1):26-31. PubMed ID: 16454978
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Use of perioperative cardiac medical therapy among patients undergoing coronary artery bypass graft surgery.
    Filion KB; Pilote L; Rahme E; Eisenberg MJ
    J Card Surg; 2008; 23(3):209-15. PubMed ID: 18435634
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of race on lipid-lowering management in hospitalized patients with coronary heart disease.
    Dressler DD; Jacobson TA
    Am J Cardiol; 2004 May; 93(9):1167-70. PubMed ID: 15110215
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel.
    Chodick G; Shalev V; Gerber Y; Heymann AD; Silber H; Simah V; Kokia E
    Clin Ther; 2008 Nov; 30(11):2167-79. PubMed ID: 19108805
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Assessment of drug treatment quality in two Danish health-care centres.
    Edfors K; Andersen SE
    Dan Med Bull; 2011 Jan; 58(1):A4218. PubMed ID: 21205564
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Secondary prevention in patients after hospitalisation due to coronary artery disease: what has changed since 2006?
    Jankowski P; Czarnecka D; Lysek R; Skrzek A; Smaś-Suska M; Mazurek A; Brzozowska-Kiszka M; Wolfshaut-Wolak R; Surowiec S; Bogacki P; Bryniarska-Mirek E; Bryniarski L; Grodecki J; Nessler J; Olszowska M; Podolec P; Kawecka-Jaszcz K; Pająk A
    Kardiol Pol; 2014; 72(4):355-62. PubMed ID: 24408064
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ischemic heart disease and primary care: identifying gender-related differences. An observational study.
    Cruz I; Serna C; Real J; Galindo G; Gascó E; Galván L
    BMC Fam Pract; 2008 Oct; 9():60. PubMed ID: 18973693
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Secondary prevention of ischemic cardiopathy].
    Caruzzo E; Caruzzo C
    Cardiologia; 1995 May; 40(5):347-53. PubMed ID: 8529246
    [No Abstract]   [Full Text] [Related]  

  • 71. [Secondary prevention of acute coronary syndrome].
    Motomiya T
    J Cardiol; 1999 Mar; 33 Suppl 1():39-43. PubMed ID: 10342135
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Attitude change of Spanish cardiologist with respect to hypolipidemic treatment in secondary prevention. The role of outside hospital care].
    Plaza Pérez I; Taboada Taboada M; Bautista Herrero Jimeno J; Gómez Guindal JA; Román León MT
    Rev Esp Cardiol; 1998; 51 Suppl 6():54-62. PubMed ID: 10050145
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The importance of validating the diagnosis of coronary heart disease when measuring secondary prevention: a cross-sectional study in general practice.
    Connolly P; Cupples ME; Cuene-Grandidier H; Johnston D; Passmore P
    Pharmacoepidemiol Drug Saf; 2002 Jun; 11(4):311-7. PubMed ID: 12138599
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Treatment of diabetic patients with ischaemic heart disease].
    Hildebrandt PR; Snorgaard O; Melchior TM; Seibaek MB; Torp-Pedersen CT
    Ugeskr Laeger; 2000 Jul; 162(31):4125-8. PubMed ID: 10962911
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of an educational program on the prevalence of use of antiplatelet drugs, beta blockers, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital discharge in patients with coronary artery disease.
    Sanal S; Aronow WS
    J Gerontol A Biol Sci Med Sci; 2003 Nov; 58(11):1046-8. PubMed ID: 14630888
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Treatment of hyperlipidemia. Guidelines for treatment of hyperlipidemia for secondary prevention of ischemic heart disease].
    Ose L
    Tidsskr Nor Laegeforen; 1995 Nov; 115(29):3629-31. PubMed ID: 8539720
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Registry of heart failure patients hospitalized in 2000. Data from the National College of Cardiology and General Hospital].
    Dujardin JJ; Hanania G; Mialet G; Bounhoure JP; Gallois H
    Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):7-10. PubMed ID: 11933561
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [The secondary prevention of coronary disease: ACE inhibitors, adrenergic beta-blockers and statins for everyone? The arguments con].
    Simões L; Guimarães J; Fontes JP
    Rev Port Cardiol; 2000 Jan; 19(1):107-13. PubMed ID: 10731796
    [No Abstract]   [Full Text] [Related]  

  • 79. Auditing secondary prevention of ischaemic heart disease in rural areas of Spain: an opportunity for improvement.
    Turón JM; Librero J; Diaz GJ; García JJ; Beltral C; Abal F;
    Eur J Gen Pract; 2006; 12(4):156-62. PubMed ID: 17127601
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Insufficient use of lipid-lowering drugs and measurement of serum cholesterol among patients with a history of myocardial infarction.
    Larsen J; Andersen M; Bjerrum L; Kragstrup J; Gram LF
    J Cardiovasc Risk; 2003 Feb; 10(1):61-4. PubMed ID: 12569238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.